Dan Peer

Dan Peer 178x219.jpgDan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is the Director of a national nanomedicine initiative project. He is also the Director of Leona M. and Harry B. Helmsley Nanotechnology Research Fund and the Chair of Tel Aviv University Cancer Biology Research Center that includes 17 affiliated hospitals.

Prof. Peer’s work was among the first to demonstrate systemic delivery of RNAi molecules using targeted nanocarriers to the immune system, and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system that has enormous implications in Cancer and inflammation.

Prof. Peer has more than 50 pending and granted patents. Some of them have been licensed to several pharmaceutical companies, and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, four spin-off companies were generated Leuko Biosciences, Quiet Therapeutics, SEPL Pharma and ART Bioscience aiming to bring personalised nanomedicine into clinical practice.

Prof. Peer a Member of the Israel Young Academy of Sciences.